Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onfekafusp alfa plus Lomustine in Recurrent Glioblastoma
NCT04573192Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Feb 2021
- Primary completion
- Mar 2025
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of onfekafusp alfa in glioblastoma (GBM), sponsored by Philogen. Started Feb 2021; status: recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04573192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573192.